Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesNMR structural analysis of a peptide mimic of the bridging sheet of HIV-1 gp120 in methanol and water.Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsFormaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsComparing antigenicity and immunogenicity of engineered gp120.Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchangePersistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirionsStructure-based vaccine design in HIV: blind men and the elephant?Is developing an HIV-1 vaccine possible?Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimeticBalance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesT-cell and neuronal apoptosis in HIV infection: implications for therapeutic intervention.Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.DNA vaccines against human immunodeficiency virus type 1 in the past decade.Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination.Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.Strategies for eliciting HIV-1 inhibitory antibodiesIn vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Inhibition of HIV-1 entry by antibodies: potential viral and cellular targetsProblems and emerging approaches in HIV/AIDS vaccine development.Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras.HIV/AIDS vaccines: a need for new concepts?Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.
P2860
Q27489000-22541D5E-3B95-4D88-98E5-779A36B50330Q28732438-5167B1F7-A4A3-4398-B832-85D37D07C7D3Q29307502-51BC7D96-1BBF-4500-8CB2-291ABBE667F8Q29619015-DEA3662E-25DD-4618-81B9-0592881E3096Q30989881-BDE2DC31-F5A3-4F84-A218-9D34DEF6CB5EQ33410222-61C9430C-5EE6-4858-B841-EE107EC07BF2Q33717477-FBC62EFC-1624-4407-9FEB-104BCE368CB5Q33724169-AAA3E90A-F27B-4124-AC0F-9BF6A5799660Q33737723-4B155C90-ADA9-4DBE-A519-F4C1A306DB7AQ33911809-26409E31-C75C-4CB3-9BCE-7DDB82E186DFQ33960361-77564AA8-D2BA-4601-84C4-0AB5354FB3B7Q33984309-65DE3974-2512-45C7-A736-EB3C6A38ECEAQ34055984-5F81C4EE-CBFB-463F-B089-40F0E65E9202Q34078508-34432D1E-09BD-46EC-84D4-AA88597BDC58Q34133986-C5AA33D4-9567-4DDA-8401-1DC7B0BEE303Q34552313-9B81870B-0FB8-4E22-9CE2-788D8E508F66Q34977075-18266AE8-62C1-4065-A23E-4D18727514F1Q34987048-387B7843-3F08-4068-B836-91B46C9689E7Q35043547-F6712A15-41D8-44C6-91F7-420796662F4AQ35058860-76DDF7EB-1A65-4771-8E69-CE84EEBE9E4CQ35065249-577666A8-C551-40BD-8C78-DD77A0855F79Q35156935-2DE77FF7-1CAA-4E26-8616-E54894164E82Q35569049-B331CCF2-5624-4626-8A48-5910312338F7Q35613792-D272DE81-4665-48EA-A54F-35735EE5F8ADQ35745442-9DF6C34A-9200-4E1E-821C-54D364CE84DFQ35745831-9568DA5C-7407-43F2-AC89-1FF1DEAC4C1AQ36099119-A17FCDB0-2B97-42C1-848A-C3DCED72FFF7Q36141515-C0276601-DBCA-42F9-AA1D-45E33B43345CQ36172480-2AC68E9A-37E8-4E9F-9666-0F6D9C931313Q36174694-83419C56-582C-4008-B6AF-F5C525ED46E1Q36452155-77BB5E9E-D6EC-4983-8409-31F716F865F9Q36529013-20B7BD34-1D73-4B20-97EB-507716DEA39CQ36541239-DDE0C998-67CF-48B5-9FB8-9E944B46656BQ36600380-EEF8084B-B069-45EA-86A9-4F02DF2B935DQ36631937-EF4A3A7E-7F89-40B4-ACA4-500CF8348FE0Q36758574-EF7F827C-45A9-45AA-B2C4-FF90162D8581Q36954218-14F07D1E-A370-49A4-9786-33CDEB3B4E77Q37344236-718578C6-C7A1-418F-B8B1-AF1F2121340BQ37730028-A9DCBE7A-F736-4296-AF76-6144ADBDB9D8Q37855900-F3D1C43B-D402-45C3-8884-B3D65F0E2A43
P2860
Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@ast
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@en
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@nl
type
label
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@ast
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@en
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@nl
prefLabel
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@ast
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@en
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@nl
P2093
P2860
P356
P1476
Crosslinked HIV-1 envelope-CD4 ...... antibodies in rhesus macaques
@en
P2093
Anthony DeVico
Carl V Hanson
Karla Godfrey
Kathryn Bobb
Ranajit Pal
Timothy Fouts
V S Kalyanaraman
P2860
P304
11842-11847
P356
10.1073/PNAS.182412199
P407
P577
2002-08-21T00:00:00Z